Student and Faculty Publications
Publication Date
2-1-2023
Journal
Lupus Science & Medicine
Abstract
OBJECTIVES: We compared the outcomes of patients with or without systemic lupus erythematosus (SLE) who were diagnosed with coronavirus disease 19 (COVID-19) and evaluated factors within patients with SLE associated with severe outcomes.
METHODS: This retrospective cohort study used the deidentified Optum COVID-19 electronic health record dataset to identify patients with COVID-19 from 1/1/2020 to 31/12/2020. Cases with SLE were matched with general controls at a ratio of 1:10 by age, sex, race and ethnicity and COVID-19 diagnosis date. Outcomes included 30-day mortality, mechanical ventilation, hospitalisation and intensive care unit admission. We evaluated the relationship between COVID-19-related outcomes and SLE using multivariable logistic regression. In addition, within SLE cases, we examined factors associated with COVID-19 related outcomes, including disease activity and SLE therapy.
RESULTS: We included 687 patients matched with 6870 controls. Unadjusted rates of outcomes for patients with SLE were significantly worse than for matched controls including mortality (3.6% vs 1.8%), mechanical ventilation (6% vs 2.5%) and hospitalisation (31% vs 17.7%) (all p
CONCLUSION: Patients with SLE had increased risk of severe COVID-19-related outcomes compared with matched controls. Patients with severe SLE disease activity or prior use of corticosteroids experienced worse outcomes.
Keywords
Humans, Lupus Erythematosus, Systemic, Retrospective Studies, COVID-19 Testing, Immunosuppressive Agents, Systemic Lupus Erythematosus, COVID-19, Antirheumatic Agents
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Community Health and Preventive Medicine Commons, COVID-19 Commons, Epidemiology Commons, Medical Sciences Commons, Oncology Commons, Rheumatology Commons
Comments
Supplementary Materials
PMID: 36787921